Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Non-Current Assets: 2020-2024

Historic Other Non-Current Assets for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $617,000.

  • Arcutis Biotherapeutics' Other Non-Current Assets fell 3.40% to $596,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $596,000, marking a year-over-year decrease of 3.40%. This contributed to the annual value of $617,000 for FY2024, which is 33.30% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Other Non-Current Assets stood at $617,000 for FY2024, which was down 33.30% from $925,000 recorded in FY2023.
  • Arcutis Biotherapeutics' Other Non-Current Assets' 5-year high stood at $1.5 million during FY2020, with a 5-year trough of $617,000 in FY2024.
  • Over the past 3 years, Arcutis Biotherapeutics' median Other Non-Current Assets value was $925,000 (recorded in 2023), while the average stood at $925,333.
  • Data for Arcutis Biotherapeutics' Other Non-Current Assets shows a maximum YoY crashed of 33.30% (in 2024) over the last 5 years.
  • Over the past 5 years, Arcutis Biotherapeutics' Other Non-Current Assets (Yearly) stood at $1.5 million in 2020, then remained steady at $1.5 million in 2021, then declined by 19.97% to $1.2 million in 2022, then dropped by 25.04% to $925,000 in 2023, then slumped by 33.30% to $617,000 in 2024.